glp 1 cold symptoms Why am I on GLP-1? Emerging research suggests that GLP-1

Individuals with T2DM frequently have multiple cardiovascular risk factors, including obesity (32.9%), hypertension (32-80%), and dyslipidemia (39%) ( The association between glycemic control and cardiovascular outcomes in DM patients has been long studied ( To address these challenges, novel pharmacological therapies such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged, offering cardioprotective benefits ( The aim of this review is to enhance our understanding of the role of SGLT-2i and GLP-1 RAs in managing patients with T2DM and CVD

Berardinelli-seip congenital lipodystrophy 2/seipin is a cell-autonomous regulator of lipolysis essential for adipocyte differentiation

How long to stay on semaglutide depends on your goals, response, and long-term weight management strategy

www.nature.com , Torekov, S